Relationship between physician specialty and allopurinol prescribing patterns: A study of patients with gout in managed care settings

Current Medical Research and Opinion

Volumn 27, Issue 4, 2011, Pages 737-744

  Pandya, Bhavik J ^a   Riedel, Aylin A ^b   Swindle, Jason P ^b   Becker, Laura K ^b   Hariri, Ali ^c   Dabbous, Omar ^a   Krishnan, Eswar ^d  

^a Takeda Pharmaceuticals International Inc   (United States)

^b i3 Innovus   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allopurinol; Gout; Physician specialty; Renal failure; Serum uric acid

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; GENERAL PRACTICE; GOUT; HUMAN; HYPERTENSION; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL SPECIALIST; NEPHROLOGIST; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOLOGY; SYSTEMATIC REVIEW; UNITED STATES; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MANAGED CARE PROGRAMS; MEDICINE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; REGISTRIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79952639543     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.552570     Document Type: Article

References (30)

1. Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007;46:623-44 (Pubitemid 47204850)
2. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7 (Pubitemid 17015410)
3. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27:337-43 (Pubitemid 23086961)
4. Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ 1996;312:173-4 (Pubitemid 26026290)
5. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56 (Pubitemid 14216359)
6. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-25 (Pubitemid 38725128)
7. Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822-9 (Pubitemid 46932089)
8. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34 (Pubitemid 43993484)
9. US National Library of Medicine. DailyMed: FDA information: allopurinol tablet. Available at http://dailymed.Nlm.nih.gov/dailymed/search.cfm?startswith= allopurinol [Last accessed 19 July 2010]
10. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4
11. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004;50:937-43 (Pubitemid 38326194)
12. Cameron JS, Simmonds HA. Use and abuse of allopurinol. Br Med J (Clin Res Ed) 1987;294:1504-5 (Pubitemid 17108382)
13. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol 2008;35:498-501 (Pubitemid 351374428)
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:s1-266
15. Rule AD, Larson TS, Bergstrahl EJ, et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141:929-37
16. National Kidney Foundation Website. KDOQI Guidelines. Available at: http://www.kidney.org/professionals/kdoqi/guidelines-ckd/toc.htm [Last accessed 12 August 2008]
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83 (Pubitemid 17055592)
18. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9 (Pubitemid 41587600)
19. Tausche AK, Jansen TL, Schröder HE, et al. Gout - current diagnosis and treatment. Dtsch Arztebl Int 2009;106:549-55
20. Halpern R, Fuldeore MJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs. J Clin Rheumatol. 2009;15:3-7
21. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24 (Pubitemid 44620440)
22. Bellamy N, Brooks PM, Emmerson BT, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 1989;151:531-2,535-7
23. Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario. J Rheumatol 1988;15:1841-7 (Pubitemid 19037657)
24. Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;67:609-13 (Pubitemid 351571922)
25. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56 (Pubitemid 14216359)
26. Dabbous OH, Fuldeore MJ, Riedel AA, et al. Allopurinol use and dose titration among individuals with renal impairment and gout [poster]. European League Against Rheumatism Annual Congress, Jun 11-14 2008, Paris, France. Ann Rheum Dis 2008;67(Suppl. II):432
27. Yu KH. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007;1:69-75
28. Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61 (Pubitemid 41781828)
29. ULORIC (febuxostat): Official Site. Available at: http://www.uloric.com [Last accessed 19 July 2010]
30. Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 2008;58:2882-91